Details of the Drug | DrugMAP

General Information of Drug (ID: DMUJ52O)

Drug Name

PCI-27483

Indication

Disease Entry	ICD 11	Status	REF
Pancreatic cancer	2C10	Phase 2	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C26H24N6O9S
Canonical SMILES: C1=CC2=C(C=C1C(=N)N)NC(=N2)C3=CC(=CC(=C3O)C4=C(C=CC(=C4)S(=O)(=O)N)O)CC(=O)NC(CC(=O)O)C(=O)O
InChI: 1S/C26H24N6O9S/c27-24(28)12-1-3-17-18(8-12)32-25(31-17)16-6-11(7-21(34)30-19(26(38)39)10-22(35)36)5-15(23(16)37)14-9-13(42(29,40)41)2-4-20(14)33/h1-6,8-9,19,33,37H,7,10H2,(H3,27,28)(H,30,34)(H,31,32)(H,35,36)(H,38,39)(H2,29,40,41)/t19-/m0/s1
InChIKey: WDJHHCAKBRKCLW-IBGZPJMESA-N

Cross-matching ID

PubChem CID: 135425273
CAS Number: 871266-63-6
TTD ID: D09TFL

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

References

1	ClinicalTrials.gov (NCT01020006) Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine. U.S. National Institutes of Health.